Versant Vantage I GP, L.P. — SEC Form 4 filings

SEC reporting owner CIK 1777651. 6 Form 4 filings on record with FilingPulse; latest filed 2025-09-23.

Transaction summary — filings shown

Covers all 6 filings on record, filed 2024-04-11 to 2025-09-23. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Monte Rosa Therapeutics, Inc. (GLUE)10% owner37 legs · 1,857,674 sh · $12,291,03510
LAVA Therapeutics NV (LVTX)10% owner28 legs · 4,587,837 sh · $6,571,090
Contineum Therapeutics, Inc. (CTNM)10% owner121

Form 4 filings — Versant Vantage I GP, L.P.

FiledFormIssuerReported transactionsSource
2025-09-234LAVA Therapeutics NV (LVTX)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage I, L.P., Versant Vantage I GP-GP, LLC
Sale (S): 2,370,533 @ $1.40 · Sale (S): 532,870 @ $1.40EDGAR
2025-09-184LAVA Therapeutics NV (LVTX)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage I, L.P., Versant Vantage I GP-GP, LLC
Sale (S): 307,707 @ $1.53 · Sale (S): 192,293 @ $1.53 · Sale (S): 362,806 @ $1.49 · Sale (S): 226,726 @ $1.49 · Sale (S): 366,111 @ $1.44 · Sale (S): 228,791 @ $1.44EDGAR
2024-10-304Monte Rosa Therapeutics, Inc. (GLUE)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage I, L.P., Versant Vantage I GP-GP, LLC
Sale (S): 89,990 @ $9.66 · Other (J): 1,019,867 @ $0 · Other (J): 20,397 @ $0 · Other (J): 20,397 @ $0 · Other (J): 17,595 @ $0 · Other (J): 17,595 @ $0 · +7 moreEDGAR
2024-09-244Monte Rosa Therapeutics, Inc. (GLUE)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage I, L.P., Versant Vantage I GP-GP, LLC
Sale (S): 1,132,566 @ $6.53EDGAR
2024-09-134Monte Rosa Therapeutics, Inc. (GLUE)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage I, L.P., Versant Vantage I GP-GP, LLC
Sale (S): 541,897 @ $6 · Sale (S): 16,047 @ $6.00 · Sale (S): 9,269 @ $6.16EDGAR
2024-04-114Contineum Therapeutics, Inc. (CTNM)
jointly with Versant Venture Capital VI, L.P., Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage I, L.P., Versant Vantage I GP-GP, LLC, Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P., Versant Ventures IV, LLC
Conversion (C): 391,785 · Conversion (C): 2,531 · Conversion (C): 148,312 · Conversion (C): 298,975 (derivative) · Conversion (C): 1,931 (derivative) · Conversion (C): 70,498 (derivative) · +15 moreEDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1777651 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →